Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

Big Phar­mas typ­i­cal­ly don’t get a lot of re­spect for R&D ef­forts. Their ROI is bad on a mas­sive an­nu­al bill, there’s too much late-stage fail­ure, an­a­lysts fret about the en­durance of big fran­chis­es and the im­pact of gener­ic com­pe­ti­tion.

Even as Pas­cal So­ri­ot is staunch­ing the bleed­ing around a bad­ly han­dled Phase III read­out for their Covid-19 vac­cine, though, the As­traZeneca CEO is tak­ing a bow to­day as Cowen lav­ish­es praise on the pipeline and near-term prospects for the multi­na­tion­al — for the sec­ond year in a row.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters